Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Abstract
Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer and overexpressed in multiple malignancies. TROP-2 is a therapeutic target for antibody–drug conjugates (ADC).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 20, 2023
- Source ID
- 10.1158/1078-0432.ccr-22-1305
Entities
People
- Anupama Singh
- Charlotte N Stahlfeld
- Christos E Kyriakopoulos
- David J Niles
- Dawei Jiang
- Erika Héninger
- Howard R Soule
- Jamie M. Sperger
- Jonathan W. Engle
- Joshua M. Lang
- Katherine R. Kaufmann
- Kyle T Helzer
- Liewei Wang
- Liguo Wang
- Manish Kohli
- Nicholas R Rydzewski
- Peng Huang
- Rendong Yang
- Scott M Dehm
- Scott T Tagawa
- Shuang G. Zhao
- Susan F. Slovin
- Weibo Cai
- Yanan Ren
Organizations
- National Cancer Institute
- Prostate Cancer Foundation
- Shenzhen University
- United States Department of Defense
- University of Minnesota
- University of Wisconsin–Madison
- Weill Cornell Medicine